Training in Pharmacology of Antineoplastic Agents

描述（由申请人提供）：药学院肿瘤内科系和骨髓移植项目赞助了一个跨学科的博士后培训项目，内容是“抗肿瘤药物的临床药理学”。“这个培训计划的目标是为个人提供开发抗肿瘤药物所需的复杂技能，评估其特性，设计临床研究，并将这些药物通过监管机构进入国家试验。参与这项培训的导师认为，有一个重要的需要，科学家谁是在化疗药物的实际评估培训，以促进这些代理从实验室工作台到床边的运动。 该计划包括2-3年的基础实验室研究培训，必要的核心课程，可用的系列讲座和选修课程。由三个合作单位的主任组成的执行委员会将管理它，由三名教师组成的导师委员会将监督学生的进步。学员将被要求写一个NIH风格的RO-1，给当地的研究研讨会，参加全国性会议，并在同行评审的期刊上发表文章。学员将由项目总监每年进行一次评估。 这项培训赠款的头四年非常成功。在完成该计划的八名受训人员中，三人加入了学术医疗中心，三人进入了工业癌症药物开发。40%的受训人员是妇女。一名西班牙裔男性和几乎相同数量的医学博士和博士接受了培训。培训补助金教师教两个新的核心课程，一个在癌症药物药理学和其他癌症生物学，成为医学院课程的一部分。 这个独特的培训计划提供了一个互动的环境，其中参与抗癌药物开发所有阶段的医学博士和博士将培训临床前和临床科学中的个人，这些科学是将抗癌药物从实验室带到床边所必需的。

DESCRIPTION (provided by applicant): The Division of Medical Oncology, School of Pharmacy, and the Bone Marrow Transplant Program sponsor an interdisciplinary postdoctoral training program in the "Clinical Pharmacology of Antineoplastic Agents." The goal of this training program is to provide individuals with the complex skills necessary to develop antineoplastic agents, evaluate their properties, design clinical studies, and move these agents through the regulatory agencies into national trials. The preceptors involved in this training believe that there is an important need for scientists who are trained in the practical evaluation of chemotherapeutic agents to facilitate the movement of these agents from the laboratory bench to the bedside. The program includes 2-3 years of basic laboratory research training, required core courses, available lecture series and elective courses. An Executive Committee consisting of the directors of the three cooperating units will administer it, and a Mentor's Committee of three faculty members will monitor student progress. Trainees will be required to write a NIH style RO-1, give local research seminars, attend national meetings, and publish articles in peer-reviewed journals. The trainees will be evaluated on a yearly basis by the Program Director. The first four years of this training grant have been extremely successful. Of the eight trainees that have completed the program, three have joined academic medical centers and three have gone into cancer drug development in industry. Forty percent of the trainees have been women. One Hispanic male and almost equal numbers of M.D.s and Ph.D.s were trained. The training grant faculty taught two new core courses, one in cancer drug pharmacology and the other in cancer biology that became part of the Medical School curriculum. This unique training program provides an interactive environment in which M.D.s and Ph.Ds involved in all phases of antineoplastic agent development will train individuals in the preclinical and clinical science necessary to take anticancer agents from the bench to the bedside.